Extra-hepatic cancer represses hepatic drug metabolism via interleukin (IL)-6 signalling

Related Experiment Video

Updated: May 12, 2026

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
08:25

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

Marina Kacevska1, Andre Mahns, Rohini Sharma

  • 1Storr Liver Unit, Westmead Millennium Institute, University of Sydney, Westmead, NSW, 2145, Australia.

Pharmaceutical Research
|April 23, 2013
PubMed
Abstract

Insights

Cancer-related inflammation, driven by tumor-produced Interleukin-6 (IL-6), reduces the liver

Area of Science:

  • Oncology
  • Pharmacology
  • Immunology

Background:

  • Cancer can impair drug metabolism in the liver, increasing the risk of severe side effects from chemotherapy.
  • The underlying mechanisms of this reduced hepatic drug clearance in cancer patients are not well understood.
  • Identifying inflammatory pathways involved is crucial for improving cancer treatment outcomes.

Purpose of the Study:

  • To investigate tumor-associated inflammatory pathways that affect drug metabolism and chemotherapy toxicity.
  • To identify the role of Interleukin-6 (IL-6) in cancer-related drug metabolism repression.
  • To explore the potential of targeting IL-6 to mitigate adverse drug reactions in cancer patients.

Main Methods:

  • Utilized a murine sarcoma model to study inflammatory pathways affecting CYP3A, a key drug-metabolizing enzyme.
  • Employed IL-6 knockout mice to determine the source of elevated IL-6 in tumor-bearing animals.
  • Administered monoclonal antibodies against IL-6 to assess its role in the inflammatory pathway.

Main Results:

  • Confirmed elevated plasma IL-6 levels and activation of Jak/Stat and Mapk signaling pathways in tumor-bearing mice.
  • Demonstrated that the tumor xenograft, not the host, was the primary source of circulating IL-6.
  • Showed that anti-IL-6 antibody treatment partially reversed tumor-induced inflammation and CYP3A gene repression.

Conclusions:

  • Interleukin-6 (IL-6) significantly contributes to cancer-induced suppression of CYP3A-mediated drug metabolism.
  • IL-6 also plays a role in activating the acute phase response associated with cancer.
  • Targeting IL-6 may offer a therapeutic strategy to reduce adverse drug events in cancer chemotherapy.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Related Concept Videos

Liver Regeneration01:24

Liver Regeneration

The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Drug Elimination: Non-Renal Routes01:23

Drug Elimination: Non-Renal Routes

The liver plays a pivotal role in eliminating drugs and their metabolites, primarily through a process known as biliary excretion. This process involves the hepatocytes, the primary cells in the liver that generate bile. A range of transporters actively expels polar drugs or hydrophilic drug metabolites into the bile, which transports the drugs and metabolites into the small intestine. From here, they are eventually expelled from the body through feces. In some instances, the original drug or a...
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...